

Outlook Therapeutics, Inc. Logo

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

November 6, 2024

Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ET

ISELIN, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- [Outlook Therapeutics, Inc.](#) (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that [Russell Trenary, President and CEO](#) of Outlook Therapeutics will participate in a fireside chat on Tuesday, November 12, 2024 at 2:30 PM ET at the [Guggenheim Healthcare Innovation Conference](#) being held in Boston, MA.

In addition to the fireside chat, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference.

A [live webcast](#) of the fireside chat will be accessible on the [Events](#) page in the [Investors](#) section of the Company's website ([outlooktherapeutics.com](#)). The webcast replay will be archived for 90 days following the event.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and the UK as a treatment for wet AMD, expected in the first half of calendar 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, is being evaluated in an ongoing non-inferiority study for the treatment of wet AMD, and if successful, the data may be sufficient for Outlook to resubmit a BLA to the FDA in the United States. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.

Investor Inquiries:

Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com



Source: Outlook Therapeutics, Inc.